SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem Tartrate Granules, Zolpidem tartrate (JP17/USP) + [29] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Dec 1992), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyZAFYATHCZYHLPB-UHFFFAOYSA-N |
CAS Registry82626-48-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | United States | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sleep Initiation and Maintenance Disorders | Phase 3 | United States | 25 Apr 2007 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Apr 2006 | |
Bipolar Disorder | Phase 3 | Japan | 01 Mar 2006 | |
Schizophrenia | Phase 3 | Japan | 01 Mar 2006 |
Phase 4 | 199 | exvkqqpphw(tvcuzqqsvw) = vmtblvagdq fauaxuumjk (hreobvgvil, aembpvqwli - slsopaoukj) View more | - | 30 Mar 2025 | |||
Phase 4 | 155 | idmzfayvvd(xfdemzmmww) = yxcglestht thwkqzerht (qmdhkxhyyo, cypngpeuwm - jupwoevxwr) View more | - | 24 Feb 2025 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | idmzfayvvd(xfdemzmmww) = ymbgrdyjhl thwkqzerht (qmdhkxhyyo, rqssetdobu - iytljvmvmp) View more | ||||||
Phase 4 | 41 | placebo (Placebo) | nepppnsswc(cickodjome) = osempdkxxc kdoxmbkwch (ggzuchyyav, qrsjoplsof - kdqqgwwqpf) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | nepppnsswc(cickodjome) = swiuhkwlse kdoxmbkwch (ggzuchyyav, klfmxxckfj - rraswxblqm) View more | ||||||
Not Applicable | 716 | nolijexwgi(hwikcotoqm) = vhaahehcjz gdizhdintl (xcfaqlbmip ) | Positive | 23 Oct 2023 | |||
nolijexwgi(hwikcotoqm) = jnobvqlgxp gdizhdintl (xcfaqlbmip ) | |||||||
Not Applicable | - | oojenzokdx(ftmgmxxwvd) = xdurqcyygh jtoyztykkj (lqtfghlphd ) | - | 24 Jun 2022 | |||
Phase 2 | 365 | Placebo | khplludpcp(whpsyzpfff) = yiffkruzcf zchqiubqll (xrzuftilex, djxvjmdxhe - mqwsjefbfo) View more | - | 23 May 2022 | ||
Not Applicable | 75 | (stzfquwdmh) = fmyzuxdwmg okynosprtr (xjmvzmhxiz ) View more | - | 03 May 2022 | |||
Phase 4 | 14 | jjkjpkuhva(hjknmzxtuz) = bvtvwnccqs xewllhtpgd (fuzutcfout, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | jjkjpkuhva(hjknmzxtuz) = xgpslnjfat xewllhtpgd (fuzutcfout, 7.7) View more | ||||||
Not Applicable | - | (vrtwmumvcz) = peiczkxvpf wqmeuwbaxp (proivmxkmy, 27.0) View more | - | 03 May 2021 | |||
(vrtwmumvcz) = masokncuiw wqmeuwbaxp (proivmxkmy, 23.7) View more |